{"id":4290,"date":"2025-06-02T23:02:20","date_gmt":"2025-06-02T23:02:20","guid":{"rendered":"https:\/\/mailitics.com\/index.php\/2025\/06\/02\/asco-cancer-news-johnson-jj-amgen-bristol-car-t-therapy-glioblastoma-day-4\/"},"modified":"2025-06-02T23:02:20","modified_gmt":"2025-06-02T23:02:20","slug":"asco-cancer-news-johnson-jj-amgen-bristol-car-t-therapy-glioblastoma-day-4","status":"publish","type":"post","link":"https:\/\/mailitics.com\/index.php\/2025\/06\/02\/asco-cancer-news-johnson-jj-amgen-bristol-car-t-therapy-glioblastoma-day-4\/","title":{"rendered":"STAT+: On ASCO Day 4, J&amp;J bets on Rybrevant and airs \u2018innovation ecosystem\u2019 concerns"},"content":{"rendered":"\n<div>STAT+: On ASCO Day 4, J&#038;J bets on Rybrevant and airs \u2018innovation ecosystem\u2019 concerns<\/div>\n<p> \t<BR><br \/>\n<BR><\/BR><br \/>\n    <!-- no image --><br \/>\n \t<BR><br \/>\n<BR><\/BR><\/p>\n<div>\n<p><em>This is the web version of STAT\u2019s\u00a0<a href=\"https:\/\/www.statnews.com\/signup\/asco-30-seconds\/\">special newslette<\/a>r from the annual meeting of the American Society of Oncology. For more updates on the latest in cancer news, sign up for our Cancer Briefing newsletter\u00a0<a href=\"https:\/\/www.statnews.com\/signup\/cancer-briefing\/\">here<\/a>.<\/em><\/p>\n<p>ASCO ends tomorrow, but alas, dear readers, this newsletter\u2019s run of show is over. At least until next year.\u00a0<\/p>\n<p>Before you digest our parting words, a couple of housekeeping notes:\u00a0<\/p>\n<p><a href=\"https:\/\/www.statnews.com\/2025\/06\/02\/asco-cancer-news-johnson-jj-amgen-bristol-car-t-therapy-glioblastoma-day-4\/?utm_campaign=rss\">Continue to STAT+ to read the full story\u2026<\/a><\/p>\n<\/div>\n<p> \t<BR><br \/>\n <BR><\/BR><br \/>\n    Adam Feuerstein, Matthew Herper, and Angus Chen<br \/>\n \t<BR><br \/>\n<BR><\/BR><br \/>\n<a href=\"https:\/\/www.statnews.com\/2025\/06\/02\/asco-cancer-news-johnson-jj-amgen-bristol-car-t-therapy-glioblastoma-day-4\/?utm_campaign=rss\">Go to statnews<\/a><br \/>\n \t<BR><br \/>\n <BR><\/BR><\/p>\n","protected":false},"excerpt":{"rendered":"<p>STAT+: On ASCO Day 4, J&#038;J bets on Rybrevant and airs \u2018innovation ecosystem\u2019 concerns This is the web version of STAT\u2019s\u00a0special newsletter from the annual meeting of the American Society of Oncology. For more updates on the latest in cancer news, sign up for our Cancer Briefing newsletter\u00a0here. ASCO ends tomorrow, but alas, dear readers, [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2733,2194,2154,2159,2208,2155,858],"tags":[2150],"class_list":["post-4290","post","type-post","status-publish","format-standard","hentry","category-asco","category-biotech","category-biotechnology","category-cancer","category-drug-development","category-pharmaceuticals","category-research","tag-statnews"],"_links":{"self":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/4290"}],"collection":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/comments?post=4290"}],"version-history":[{"count":0,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/4290\/revisions"}],"wp:attachment":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/media?parent=4290"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/categories?post=4290"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/tags?post=4290"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}